Moderna Inc (MRNA)

329.63
+56.24(+20.57%)
After Hours
336.05
+6.42(+1.95%)
- Real-time Data
  • Volume:
    35,874,860
  • Bid/Ask:
    336.05/336.48
  • Day's Range:
    313.00 - 350.15

MRNA Overview

Prev. Close
273.39
Day's Range
313-350.15
Revenue
11.83B
Open
319.34
52 wk Range
102.68-496.71
EPS
16.28
Volume
35,874,860
Market Cap
133.65B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
12,885,663
P/E Ratio
16.79
Beta
-
1-Year Change
150.4%
Shares Outstanding
405,449,527
Next Earnings Date
09 Mar 2022
What is your sentiment on Moderna Inc?
or
Market is currently closed. Voting is open during market hours.

Moderna Inc Company Profile

Employees
1300

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuyStrong BuyBuy
Technical IndicatorsStrong SellBuyStrong BuyStrong BuyStrong Buy
SummarySellBuyStrong BuyStrong BuyStrong Buy
  • Go above 300 next week
    0
    • Going back to 150 soon
      7
      • The trick to investing in cyclical stock (one hit wonder) is to buy when pe is high and sell when PE is at the lowest.
        1
        • And do you guys think it will pull up again?
          2
          • Hello guy i just made a mistake i didn’t sell my moderna stock earlier. But is it a good time to sell or i should just leave it
            6
            • Will be looking to open up a position at these prices.
              0
              • Was way overpriced.. given the multiples and the fact that novavax will take considerable market share from it going forward. Sell moderna but novavax. No brainer from a valuation point. When countries / people are given a choice to take a vaccine with heart inflammation issues (albeit small) v a proven protein based method method of manufacture, which is safer, as effective, logistically easier to distribute.. its a no brainer which on you choose in my opinion.
                7
                • Is it still overpriced? Where should be fair value around $100?
                  0
              • It should find buyers at this level. Just my opinion.
                2
                • what next for this stock?
                  0
                  • damn
                    0
                    • Good product
                      0
                      • Good product
                        0
                        • should I sell
                          2
                          • Buy
                            3
                            • Can anyone advice, still good to buy or should sell?
                              4
                              • Best time to buy was last year.
                                1
                              • PE ratio below others with higher revenues which is great. I think the concern is declinig revenues.
                                0
                              • i advise is to sell and wait and watch. it should touch usd. 150 or probably lower. Parker
                                1
                            • Keep shorting. More competitors like MRK are entering covid vaccine/therapy space.
                              1
                              • Incredible it falling down to 300 or 200
                                0
                                • Yes,this is incredible
                                  0
                              • Impossible stock falling!
                                1
                                • incredible
                                  0
                              • Do it will be down to 200 ?
                                0
                                • Most probably
                                  0
                              • Doooooown
                                0
                                • why we goes down?
                                  1
                                  • going 5% down sell on
                                    0
                                    • will close in green
                                      2
                                      • gentlemen good morning, as usual, I extend the invitation to anyone who is intrigued or interested in meeting new companies. In that case, so as not to bother the modernists of this forum further, switch over to Verrica Pharmaceuticals. Good gain to all. Ibanez.
                                        0
                                        • go faster bi10ch
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.